Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

DART Meets Noninferiority PFS Benchmark in HPV-Related OPSCC

February 25, 2022
By Audrey Sternberg
Article
Conference|Multidisciplinary Head and Neck Cancers Symposium

In a pre-planned pooled analysis of data from the MC1273 and MC1675 trials presented at the 2022 ASTRO Multidisciplinary Head and Neck Cancers Symposium, de-escalated adjuvant radiation therapy met criteria for efficacy in human papillomavirus–related oropharyngeal squamous cell carcinoma.

A pooled analysis of data supporting the use of de-escalated adjuvant radiation therapy (DART) for human papillomavirus (HPV)–related oropharyngeal squamous cell carcinoma (OPSCC) met the noninferiority threshold for progression-free survival (PFS) compared with historical data, further supporting its use as a less toxic regimen in this setting.1

Compared with PFS results from the HN055 trial (NCT03952585), the 2-year PFS rates of 91.1% (95% CI, 87.2%-95.3%) was within the acceptable threshold of noninferiority, according to Daniel J. Ma, MD, who presented the data at the 2022 Multidisciplinary Head and Neck Cancers Symposium hosted by the American Society for Radiation Oncology (ASTRO).

“Progression-free survival is the aim to see if [DART] meets the metric that was set as clinically acceptable by the head and neck community,” Ma, coleader of the Oropharynx Multidisciplinary Clinic at Mayo Clinic, said during the presentation. “This is the largest prospective cohort of [patients treated with] de-escalated adjuvant therapy and represents the only prospective cohort of extranodel extension [ENE]–positive disease with radiation dose de-escalation.”

Background of MC1273 and MC1675

Due to the severity of adverse effects associated with therapies for HPV-related oropharyngeal cancers, investigators set out to examine a 2-week course of 30 to 36 Gy adjuvant radiation therapy for selected patients by way of the phase 2 MC1273 (NCT01932697) and phase 3 MC1675 trials (NCT02908477).

MC1273 examined patients with surgically resected p16-positive OPSCC who had no evidence of metastases and less than a 10 pack-year smoking history and stratified them by adjuvant risk factors. Patients who had intermediate risk factors only, defined by lymphovascular or perineural invasion, were in cohort A and were administered 30 Gy delivered in 1.5 Gy increments twice daily over 12 days with docetaxel at 15 mg/m2 on days 1 and 8; those with extranodal extension who were in cohort B and were given 36 Gy delivered in 1.8 Gy increments twice daily over 12 days with docetaxel.2

Positive results led to MC1675, in which the DART regimens described above were randomized against standard therapy in a 2:1 fashion. In cohort A, 53 patients were treated with DART whereas 26 were given 60 Gy delivered in 2 Gy doses; cohort B consisted of 77 patients on DART and 38 who were given 60 Gy as 2 Gy doses plus 40 mg/m2 of cisplatin weekly.3

“Results from MC1675 have demonstrated excellent overall survival, locoregional control, and progression-free survival metrics,” Ma said.

However, questions about the DART regimen remain, such as whether the PFS results are clinically acceptable, leading to the current pooled analysis of both trials.

“This is a bit of a philosophical question about what is meant by clinically acceptable. The gold standard is a randomized phase 3 trial powered for noninferiority,” said Ma. He then pointed out that to achieve statistically significant results in a trial like MC1675, 4000 patients would be needed to achieve a 1% noninferiority margin. “This is more than all the patients with TORS [transoral robotic surgery] across all the academic centers across the United States with a year.”

Ma then referred to the HN005 trial with hierarchical co-primary end points of PFS and quality of life, in which patients were first analyzed for PFS noninferiority vs a comparable population treated in RTOG 1016 (NCT01302834). When the end point was reached, subsequent comparisons for global MD Anderson Dysphagia Inventory (MDADI) were performed between arms.

“The design for this pre-planned joint analysis is to repeat the HN005 composite design, but in reverse,” said Ma. Given the toxicity results of MC1675 have been presented, the composite analysis is being performed based on efficacy results of MC1675 and MC1273 pooled results.

DART Efficacy Noninferiority

Accrual across the 2 trials occurred from 2013 to 2020 with a median follow-up time of 36.6 months. Those who were included in the pooled analysis received DART in either MC1675 (n = 130) or MC1273 (n = 72). One patient was lost to follow-up due to incarceration around the 12-month time point.

Using the 2-year PFS rate of 92.3% and the lower acceptable threshold of 86.9% from HN005, the investigators for the current analysis determined that DART meet noninferiority.

Looking at subgroups, the ENE-negative cohort remains above the pre-determined PFS threshold with a 2-year rates of 97.7% (95% CI, 94.6%-100.0%); however, patients with ENE-positive status drop below the threshold with a rate of 85.2% (95% CI, 78.6%-92.5%).

Drilling down into each subgroup further, all prespecified cohorts met the noninferiority margin except those with ENE-positive pN2 disease, with a 2-year PFS rate of 54.5% (95% CI, 36.4%-81.7%). Corresponding rates were 97.5% (95% CI, 94.7%-100.0%) with ENE-negative pN0-1 disease, 100.0% for ENE-negative pN2, and 92.5% (95% CI, 86.9%-98.5%) in ENE-positive pN1 disease. Ma cautioned against interpretation of the ENE-negative pN2 cohort, as there were only 2 patients enrolled.

“Most of the events of progression happened in the ENE-positive, pN2 cohort,” Ma said.

Further, the extent of ENE—either values of less than 1 mm vs 1 mm or more—had no appreciable contribution on PFS.

For the combined cohort, rates of overall survival and locoregional control at 2 years were 97.8% (95% CI, 95.7%-100.0%) and 96.9% (95% CI, 94.5%-99.4%), respectively.

“Going back to the question we posed and understanding that this is somewhat controversial, are the results of the DART regimen clinically acceptable? I’ll leave that to the community to define, but I will say that the DART regimen does meet the HN005 PFS noninferiority target. This is combined with the fact that there is a substantial toxicity benefit seen with the DART regimen,” Ma concluded.

References

  1. Ma DJ, Price K, Moore EJ, et al. Non-inferiority margin and nodal analysis of de-escalated adjuvant radiation therapy (DART) for HPV-related oropharyngeal squamous cell carcinoma (OPSCC): a preplanned pooled analysis of MC1273 & MC1675. Presented at: 2022 Multidisciplinary Head and Neck Symposium; February 24-26, 2022; Phoenix, AZ. Abstract 2. Accessed February 24, 2022. https://bit.ly/3BUCTyn
  2. Ma DJ, Price K, Moore EJ, et al. Long-Term results for MC1273, a phase II evaluation of de-escalated adjuvant radiation therapy for human papillomavirus associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC). Intl J Rad Oncol Biol Phys. 2021;111(3):S61. doi: 10.1016/j.ijrobp.2021.09.012
  3. Ma DJ, Price K, Moore EJ, et al. MC1675, a phase III evaluation of de-escalated adjuvant radiation therapy (DART) vs. standard adjuvant treatment for human papillomavirus associated oropharyngeal squamous cell carcinoma. Intl J Rad Oncol Biol Phys. 2021;111(5):LBA-1. doi: 10.1016/j.ijrobp.2021.09.012
Recent Videos
The Jack & Sheryl Morris Cancer Center offers “state-of-the-art” surgical suites and advanced radiation technology, says Andrew M. Evens, DO, MBA, MSc.
A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
Focused, high-dose radiotherapy doses may prolong survival and the interval to subsequent therapy for patients with advanced prostate cancer.
Data show increasing use of proton therapy overall but widening gaps in populations who have access to this treatment, says Curtiland Deville Jr., MD.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Related Content
Advertisement

Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Tim Cortese
May 29th 2025
Article

Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.


A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Elucidating Noninvasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD
April 28th 2025
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.


IMRT Does Not Improve Tolerability vs 3D-CRT in Advanced Rectal Cancer

IMRT Does Not Improve Tolerability vs 3D-CRT in Advanced Rectal Cancer

Tim Cortese
May 27th 2025
Article

Intensity-modulated radiotherapy increased some lower-grade toxicities vs 3D conformal radiotherapy in patients with locally advanced rectal cancer.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Navigating the Landscape of PSMA PET Imaging Agents in Prostate Cancer

Navigating the Landscape of PSMA PET Imaging Agents in Prostate Cancer

ONCOLOGY Staff
May 24th 2025
Article

Prostate-specific membrane antigen PET imaging has completely altered the landscape of prostate cancer detection and management. Read as several experts discuss the trajectory and growth of these agents.


From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.

ASCO 2025: The Presentations That May Shift the Cancer Care Paradigm

Russ Conroy
May 23rd 2025
Article

From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.

Related Content
Advertisement

Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Tim Cortese
May 29th 2025
Article

Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.


A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Elucidating Noninvasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD
April 28th 2025
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.


IMRT Does Not Improve Tolerability vs 3D-CRT in Advanced Rectal Cancer

IMRT Does Not Improve Tolerability vs 3D-CRT in Advanced Rectal Cancer

Tim Cortese
May 27th 2025
Article

Intensity-modulated radiotherapy increased some lower-grade toxicities vs 3D conformal radiotherapy in patients with locally advanced rectal cancer.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Navigating the Landscape of PSMA PET Imaging Agents in Prostate Cancer

Navigating the Landscape of PSMA PET Imaging Agents in Prostate Cancer

ONCOLOGY Staff
May 24th 2025
Article

Prostate-specific membrane antigen PET imaging has completely altered the landscape of prostate cancer detection and management. Read as several experts discuss the trajectory and growth of these agents.


From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.

ASCO 2025: The Presentations That May Shift the Cancer Care Paradigm

Russ Conroy
May 23rd 2025
Article

From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.